Area of research
Pulmonary and Respiratory Medicine · Molecular Biology
Research interest
Research interests include Renal cell carcinoma treatment, Renal and related cancers, Cancer Genomics and Diagnostics, and Epigenetics and DNA Methylation.
Tuberous sclerosis complex-associated renal cell carcinoma, an underappreciated form of familial renal cancer, is characterized by activation of the TFEB/TFE3 pathway.
Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis.
Supplementary Figure S6 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of <i>ALK</i> Fusion Gene-Associated Renal Tumorigenesis
Supplementary Figure S4 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of <i>ALK</i> Fusion Gene-Associated Renal Tumorigenesis
Supplementary Table S2 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of <i>ALK</i> Fusion Gene-Associated Renal Tumorigenesis
Supplementary Figure S3 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of <i>ALK</i> Fusion Gene-Associated Renal Tumorigenesis
Data from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of <i>ALK</i> Fusion Gene-Associated Renal Tumorigenesis
Supplementary Table S3 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of <i>ALK</i> Fusion Gene-Associated Renal Tumorigenesis
Supplementary Table S2 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of <i>ALK</i> Fusion Gene-Associated Renal Tumorigenesis
Supplementary Table S1 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of <i>ALK</i> Fusion Gene-Associated Renal Tumorigenesis
Supplementary Figure S1 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of <i>ALK</i> Fusion Gene-Associated Renal Tumorigenesis
Supplementary Figure S5 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of <i>ALK</i> Fusion Gene-Associated Renal Tumorigenesis
Supplementary Figure S2 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of <i>ALK</i> Fusion Gene-Associated Renal Tumorigenesis
Supplementary Table S1 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of <i>ALK</i> Fusion Gene-Associated Renal Tumorigenesis
Supplementary Figure S6 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of <i>ALK</i> Fusion Gene-Associated Renal Tumorigenesis
Supplementary Table S3 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of <i>ALK</i> Fusion Gene-Associated Renal Tumorigenesis
Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82.
Comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers.
Supplementary Figure S11 from Targeting NAD<sup>+</sup> Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Supplementary Figure S10 from Targeting NAD<sup>+</sup> Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Supplementary Figure S9 from Targeting NAD<sup>+</sup> Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Supplementary Figure S7 from Targeting NAD<sup>+</sup> Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Supplementary Figure S5. from Targeting NAD<sup>+</sup> Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Supplementary Figure S6. from Targeting NAD<sup>+</sup> Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Supplementary Table S1 from Targeting NAD<sup>+</sup> Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Supplementary Figure S8 from Targeting NAD<sup>+</sup> Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Supplementary Figure S2. from Targeting NAD<sup>+</sup> Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Is Active Surveillance a Suitable Approach for Bilateral Multifocal Renal Oncocytomas? The 20-Year National Cancer Institute Experience
Data from Targeting NAD<sup>+</sup> Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Supplementary Figure S1 from Targeting NAD<sup>+</sup> Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82